Loading…
Accretion Nutraveda (BSE 544694)₹329.00+5.79%Pharmaceuticals
In the Mar 2026 quarter (standalone), Accretion Nutraveda reported sales of ₹19.56 Cr, up 80.4% from Mar 2025, and net profit of ₹2.70 Cr, up 56.1% year on year. For the year to Mar 2026, sales were ₹33.62 Cr and net profit ₹5.09 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 10.84 | 14.07 | 19.56 |
| Expenses | 8.29 | 10.79 | 16.04 |
| Operating Profit | 2.59 | 3.31 | 3.57 |
| OPM % | 23.8% | 23.5% | 18.3% |
| Other Income | 0.00 | 0.00 | 0.10 |
| Interest | 0.25 | 0.25 | 0.26 |
| Depreciation | 0.12 | 0.18 | 0.11 |
| Profit before tax | 2.20 | 2.86 | 3.29 |
| Tax % | 22.2% | 18.5% | 18.5% |
| Net Profit | 1.73 | 2.34 | 2.70 |
| EPS (Rs) | 35.19 | 4.37 | 3.70 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 2.90 | 5.02 | 15.99 | 33.62 |
| Expenses | 2.28 | 3.79 | 12.32 | 26.79 |
| Operating Profit | 0.63 | 1.24 | 3.72 | 6.91 |
| OPM % | 21.5% | 24.6% | 23.2% | 20.6% |
| Other Income | 0.16 | 0.18 | 0.00 | 0.10 |
| Interest | 0.18 | 0.23 | 0.34 | 0.52 |
| Depreciation | 0.32 | 0.27 | 0.23 | 0.27 |
| Profit before tax | 0.28 | 0.91 | 3.14 | 6.20 |
| Tax % | 3.5% | 9.8% | 20.7% | 18.4% |
| Net Profit | 0.29 | 0.83 | 2.51 | 5.09 |
| EPS (Rs) | 7.75 | 22.71 | 51.14 | 6.97 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.35 | 0.36 | 0.48 | 7.23 |
| Reserves | −0.11 | 0.72 | 4.55 | 28.25 |
| Borrowings | 1.98 | 2.18 | 3.87 | 4.24 |
| Other Liabilities | 1.84 | 1.39 | 1.64 | 2.09 |
| Total Liabilities | 4.06 | 4.65 | 10.54 | 41.81 |
| Fixed Assets | 1.50 | 1.29 | 1.84 | 1.67 |
| CWIP | 0.00 | 0.09 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 2.56 | 3.27 | 8.70 | 40.14 |
| Inventories | 1.31 | 2.39 | 4.60 | 9.01 |
| Trade receivables | 0.79 | 0.24 | 3.26 | 8.09 |
| Cash & equivalents | 0.10 | 0.13 | 0.03 | 9.77 |
| Total Assets | 4.06 | 4.65 | 10.54 | 41.81 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 0.69 | 0.22 | −2.23 | −9.43 |
| Cash from investing activity | −0.02 | −0.17 | −0.88 | −14.53 |
| Cash from financing activity | −0.62 | −0.03 | 2.97 | 25.15 |
| Net cash flow | 0.03 | 0.02 | −0.09 | 1.25 |
| Capex | 0.02 | 0.17 | 0.88 | 6.05 |
| Free cash flow | 0.68 | 0.08 | −3.10 | −15.50 |
| CFO / OP % | 110.0% | 27.0% | −42.0% | −113.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 102 | 19 | 76 | 89 |
| Inventory days | 280 | 305 | 160 | 137 |
| Days payable | 353 | 113 | 30 | 10 |
| Cash conversion cycle | 26 | 208 | 202 | 213 |
| Working capital days | 9 | 7 | 129 | 196 |
| ROCE % | — | 42.4% | 57.6% | 27.8% |
For the Mar 2026 quarter, Accretion Nutraveda reported sales of ₹19.56 Cr, up 80.4% year on year and net profit of ₹2.70 Cr, up 56.1% year on year. The operating margin was 18.3%.
Accretion Nutraveda's sales for the year to Mar 2026 were ₹33.62 Cr.
Net profit for the year to Mar 2026 was ₹5.09 Cr. Earnings per share over the same trailing period were ₹6.97.
Accretion Nutraveda reported borrowings of ₹4.24 Cr at Mar 2026, against cash and equivalents of ₹9.77 Cr.
Cash from operations was −₹9.43 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹15.50 Cr.